Catatonia Atlas
Atlas reading guideEvidence source

Published CONNEX phase 3 program

Open this page in the complete interactive Atlas

Reports individual and pooled findings from the three 26-week randomized trials.

Where this source fits

Iclepertin · Cognitive impairment associated with schizophrenia

Over 26 weeks, the pooled difference on the standardized cognitive battery was 0.13 T-score points, with a 95% confidence interval from −0.40 to 0.65. No meaningful cognitive advantage emerged.

The outcome was cognition, including capacities such as attention and memory. These results do not test treatment of hallucinations or catatonia.

Reading basis · Original source summarized in the experimental-drug section

Experimental drugs research

Original source

https://pubmed.ncbi.nlm.nih.gov/41233083/